Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive PLC RNS Release

Result of AGM


RNS Number : 8820X
Genedrive PLC
29 November 2017
 

For release: 29 November 2017

 

genedrive plc ("genedrive" or the "Company")

 

Result of AGM

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held in Manchester today, all resolutions proposed were duly passed.

 

-  Ends  -

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO


Matthew Fowler: CFO




Peel Hunt LLP

+44 (0)207 418 8900

James Steel


Oliver Jackson




Consilium Strategic Communications

+44 (0)203 709 5700

Chris Gardner


Matthew Neal


Laura Thornton


[email protected]


 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has received CE-IVD Certification.

Further details can be found at:  www.genedriveplc.com  and  www.genedrive.com  

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBSBDBUBDBGRC

Genedrive PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use